Glycerol Phenylbutyrate 相關新聞
Glycerol Phenylbutyrate 目前有 0 則相關新聞報導,預測適應症 20 個。
本頁整合 Glycerol Phenylbutyrate 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
- 原適應症:Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine...
- 證據等級:L5
- 預測適應症(20 個):
- urea cycle disorder(98.7%)
- argininosuccinic aciduria(98.2%)
- carbamoyl phosphate synthetase I deficiency disease(97.9%)
- acute neonatal citrullinemia type I(97.2%)
- adult-onset citrullinemia type I(97.2%)
- citrullinemia, type II, adult-onset(97.1%)
- 3-methylcrotonyl-CoA carboxylase 1 deficiency(97.1%)
- hyperinsulinism-hyperammonemia syndrome(96.8%)
- hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency(96.6%)
- hyperargininemia(95.0%)
- citrullinemia(94.3%)
- citrin deficiency(93.5%)
- neonatal intrahepatic cholestasis due to citrin deficiency(92.7%)
- benign neoplasm of adrenal gland(90.8%)
- hyperammonemia due to N-acetylglutamate synthase deficiency(89.0%)
- familial apolipoprotein C-II deficiency(86.3%)
- polycystic kidney disease 3 with or without polycystic liver disease(83.1%)
- acute intermittent porphyria(81.3%)
- renal-hepatic-pancreatic dysplasia(79.6%)
- autosomal ichthyosis syndrome with fatal disease course(79.5%)
相關新聞(0 則)
目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。
免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。